oral semaglutide approval Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Drug Watch: The oral version

doi: 10.1016/j.nlm.2021.107463 65 WangXChenJRongCPanFZhaoXHuY

This means it activates not only the GLP-1 receptor, but also the GIP (glucose-dependent insulinotropic polypeptide) receptor pathway

Naltrexone carries a black-box warning for liver toxicity, and semaglutide has gastrointestinal and pancreatitis risks

1 L-carnitine has been shown in animal models to stabilize mitochondrial membranes, increase energy delivered to organelles, and protect against cellular apoptotic death

This may be primarily of relevance for the cephalic phase insulin response, preparing for incoming food rather than signaling taste per se [27]